baofeng wang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. baofeng wang | Cancer Cell Biology | Best Researcher Award

Prof. baofeng wang, Department of Radiation Therapy, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an 710004, China, China

Dr. Baofeng Wang is a Professor and Associate Chief Physician at The Second Affiliated Hospital of Xi’an Jiaotong University. He serves as Head of the Abdominal Oncology Group in the Department of Radiation Oncology and is a Master’s Supervisor. Renowned for his expertise in abdominal and liver cancers, Dr. Wang actively contributes to several professional organizations, including the Chinese Society for Radiation Oncology (CSRO). As a reviewer for top journals and a recipient of multiple prestigious research awards, his work integrates clinical excellence with cutting-edge research. He has led three national and provincial-level projects and has authored over 40 scientific articles, with more than 10 published in SCI-indexed journals. His recent work focuses on ferroptosis, immune regulation in cancer, and BNCT treatment planning, marking him as a leading figure in translational oncology research.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Academic and Clinical Leadership:

    • Professor, Associate Chief Physician, and Master’s Supervisor.

    • Head of the Abdominal Oncology Group at a leading national medical institution.

    • Actively leads and shapes treatment protocols in radiation oncology.

  2. Research Productivity and Impact:

    • Authored over 40 scientific publications, with more than 10 indexed in SCI journals.

    • Principal Investigator for 3 major funded research projects.

    • Co-investigator in 5 additional national and provincial projects.

    • Reviewer for high-impact international journals, ensuring scientific rigor in oncology research.

  3. Recognition and Awards:

    • Winner of two First Prizes for Scientific and Technological Progress in Higher Education Institutions.

    • Received a Second Prize from the Shaanxi Provincial Scientific and Technological Progress Awards.

  4. Professional Influence:

    • Holds multiple key positions in national and provincial medical societies, especially within the Chinese Society for Radiation Oncology (CSRO).

    • Active in bridging research, clinical practice, and public health education.

  5. Recent Research Focus:

    • Investigating mechanisms of radioresistance via ferroptosis and cholesterol metabolism.

    • Advancing boron neutron capture therapy (BNCT) planning and immunoregulatory pathways in breast cancer and hepatocellular carcinoma.

⚙️ Areas for Improvement:

  1. Global Collaboration:

    • While domestically influential, expanding international collaborations and partnerships could further elevate the research impact and visibility.

  2. Citation Index and Research Translation:

    • Despite a good number of publications, a higher citation count and more translational outcomes into clinical practice would strengthen the award candidacy further.

  3. Innovation Leadership:

    • Developing patents or pioneering novel therapeutic technologies would add to innovation metrics.

🎓 Education:

Dr. Baofeng Wang received rigorous academic training in the medical sciences, specializing in oncology and radiation therapy. After completing his undergraduate medical degree, he pursued postgraduate studies focused on radiation oncology and tumor biology. His advanced academic pursuits led to a comprehensive understanding of radiobiology, imaging-guided radiotherapy, and molecular oncology. He continuously updates his knowledge through professional development programs and has contributed to both educational and research domains by mentoring postgraduate students. His commitment to academic excellence is evident through his role as a Master’s Supervisor, guiding the next generation of clinical researchers. Dr. Wang’s educational background has equipped him with the skills necessary to integrate evidence-based medicine with innovative research, particularly in the fields of liver cancer and immuno-oncology.

🧪 Professional Experience:

With over 15 years of clinical and academic experience, Dr. Baofeng Wang is a leading figure in the field of radiation oncology. Currently a Professor and Associate Chief Physician, he heads the Abdominal Oncology Group at The Second Affiliated Hospital of Xi’an Jiaotong University. He has been instrumental in developing individualized radiotherapy protocols for complex tumors. His leadership roles in various national and provincial oncology organizations highlight his influence in shaping cancer treatment strategies. He has served as Principal Investigator for several research grants from the National Natural Science Foundation of China and provincial R&D bodies. Additionally, Dr. Wang plays an active role in academic peer review and science promotion in Shaanxi province. His blend of clinical acumen and research proficiency makes him a cornerstone in the advancement of radiotherapy techniques and translational oncology.

🔬 Research Focus:

Dr. Wang’s research focuses on the intersection of radiation oncology, tumor metabolism, and immunoregulation. He investigates how cellular mechanisms such as ferroptosis and cytokine modulation contribute to radioresistance and tumor progression. A major area of interest is the optimization of boron neutron capture therapy (BNCT) treatment planning, aiming to enhance therapeutic outcomes in abdominal cancers. His work also explores the role of tumor-infiltrating immune cells and how factors like interleukin-10 influence immune suppression and therapy response. By integrating molecular diagnostics with imaging-guided radiotherapy, Dr. Wang seeks to improve precision medicine strategies. His translational research aims to convert lab-based discoveries into clinically viable cancer treatments, particularly for liver, breast, and gastrointestinal cancers. Through collaborative and interdisciplinary research, Dr. Wang’s work continues to push boundaries in oncology innovation.

📚 Publications Top Notes:

  1. 🧬 Recent research progress of BNCT treatment planning system

  2. 🔗 SCARB1 links cholesterol metabolism-mediated ferroptosis inhibition to radioresistance in tumor cells

  3. 🎯 BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

  4. 🛡️ Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

📌 Conclusion:

Dr. Baofeng Wang exemplifies the qualities of an exceptional clinical researcher, balancing leadership, clinical service, and impactful research. His contributions to radiation oncology—particularly in abdominal and liver cancers—along with national-level recognition and funding, make him a highly suitable and competitive candidate for the Best Researcher Award. Continued expansion of his international footprint and translational outputs would position him even more prominently on the global stage.

Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Dr. Mingkun Yu , Binzhou Medical College Affiliated Traditional Chinese Medicine Hospital(Binzhou Traditional Chinese Medicine Hospital) , China

Dr. Mingkun Yu is an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, affiliated with Binzhou Medical College, China. He is an expert in integrating evidence-based medicine with traditional Chinese and Western medical practices, especially within oncology and ophthalmology. With over five years of clinical experience, Dr. Yu has made significant contributions to the field through impactful clinical research, trial designs, and methodological innovation. He is the recipient of a National Natural Science Foundation of China project and has led the development of national-level guidelines. Dr. Yu’s publications have gained high visibility, with citations and downloads from prestigious journals like BMJ. He collaborates with renowned experts worldwide and actively contributes as a peer reviewer for SCI journals. Known for his meticulous clinical approach and research rigor, Dr. Yu is a rising star in integrative medical science, particularly in addressing patient compliance and advancing myopia-related research strategies.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Academic Excellence
    Dr. Yu has earned advanced degrees from top-tier traditional Chinese medicine institutions in China, culminating in a PhD focused on integrated clinical medicine—a rare and interdisciplinary specialty.

  2. Proven Research Record

    • Published 7 SCI-indexed papers (including in BMJ and Therapeutic Advances in Gastroenterology) and 5 Chinese core journal papers.

    • First/corresponding author impact factor: 18.3; co-author cumulative impact factor: 112.

    • One article with 9248 downloads, another cited 66 times—demonstrating strong academic reach and relevance.

  3. Research Leadership

    • Designed and led multiple RCTs, cohort studies, and cluster RCTs.

    • Principal investigator of a National Natural Science Foundation of China project.

    • Spearheaded the national-level guideline on myopia—a major public health concern in Asia.

  4. Innovative Contributions

    • Introduced target value analysis and conducted extensive patient compliance research in clinical trials.

    • Integrated evidence-based methods with traditional Chinese medicine, a cutting-edge niche in global medical research.

  5. Collaborations & Peer Review

    • Collaborates with global leaders such as Paul Little, Gordon Guyatt, and Lehana Thabane.

    • Reviewer for top SCI journals including European Journal of Integrative Medicine and BMC Geriatrics.

⚙️ Areas for Improvement:

  1. Global Dissemination & Outreach

    • Dr. Yu could further enhance his profile by increasing international speaking engagements, attending more global medical symposia, and joining international research societies.

  2. Books or Monographs

    • No books published yet. Authoring clinical reference books or practitioner guides would boost both practical impact and professional visibility.

  3. Translational Research and Patents

    • With only one published patent, there is scope to convert more research findings into innovative tools, treatments, or technologies for broader clinical application.

  4. Professional Memberships

    • Active memberships in professional research or clinical bodies could enhance his professional network and visibility in award circuits.

📚 Education:

Dr. Yu earned his Master’s degree in Evidence-Based Medicine (Oncology) from Beijing University of Traditional Chinese Medicine in 2021. His academic journey culminated in a PhD in Clinical Medicine (Integrated Traditional Chinese and Western Medicine) from Shandong University of Traditional Chinese Medicine in 2024. Throughout his education, Dr. Yu focused on bridging the gap between traditional Chinese therapeutic principles and contemporary Western medical methodologies. His doctoral research emphasized designing clinical trials, evaluating treatment efficacy using systematic review and meta-analysis, and developing methodologies for improving patient outcomes. His educational background also provided him with comprehensive knowledge in oncology, ophthalmology, acupuncture, and behavioral health, preparing him to implement innovative, integrative solutions in clinical practice. He was mentored by leading figures in evidence-based medicine and engaged in collaborative studies with international researchers, further enriching his global research perspective.

🩺 Experience:

With more than 5 years of experience in clinical medicine, Dr. Mingkun Yu has become a prominent practitioner and researcher in integrated traditional Chinese and Western medical care. As an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, he leads and participates in high-level clinical research projects, including randomized controlled trials and cohort studies. He has contributed to over 7 national-level research projects and served as principal investigator in hospital-based clinical studies. Dr. Yu’s areas of expertise include patient compliance strategies in oncology, evidence synthesis in myopia prevention, and methodological development for clinical trials. He is a frequent presenter at national and international conferences and has served as a reviewer for SCI-indexed journals. Dr. Yu is also involved in writing clinical practice guidelines and has been recognized for his scientific contributions through research awards and publications in high-impact journals.

🔬 Research Focus:

Dr. Mingkun Yu’s research lies at the intersection of evidence-based medicine and integrated Chinese and Western clinical practices. His key focus areas include patient compliance in oncology, risk factor identification and prevention strategies for myopia, and designing robust clinical trials like RCTs, cohort, and cluster studies. He actively develops and applies systematic review methodologies, meta-analyses, and guideline development processes to ensure high-impact clinical outcomes. Dr. Yu has innovated in the area of patient compliance by applying qualitative synthesis and target value analysis, improving retention and adherence in clinical trials. He is particularly invested in the development of guidelines for myopia in children and adolescents and has published widely in SCI journals. His collaboration with global experts such as Paul Little, Gordon Guyatt, and Lehana Thabane strengthens the international relevance of his work. Through this multifaceted research approach, Dr. Yu aims to bridge traditional wisdom with modern scientific rigor.

📝 Publications Top Notes:

📄 Pseudomyopia as an independent risk factor for myopia onset: a prospective cohort study among school-aged children – British Journal of Ophthalmology, 2024
📘 The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative research – Inplasy Report, 2021
📚 Berberine for diarrhea in children and adults: a systematic review and meta-analysis – Therapeutic Advances in Gastroenterology, 2020

🧾 Conclusion:

Dr. Mingkun Yu stands out as a highly deserving candidate for the Best Researcher Award due to his cross-disciplinary research integrating traditional Chinese and Western medicine, his leadership in national clinical trials, impactful publications, and commitment to clinical innovation. His scholarly output is not only substantial but also highly cited and widely read, reflecting real-world influence and academic excellence.

With a growing international research presence, a unique focus on culturally integrated methodologies, and an impressive trajectory of innovation and collaboration, Dr. Yu clearly embodies the ideals of a next-generation clinical research leader.

Miroslaw Markiewicz | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Miroslaw Markiewicz | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Miroslaw Markiewicz , Faculty of Medicine, Collegium Medicum, University of Rzeszow , Poland

Mirosław Markiewicz is a distinguished medical professional specializing in hematology, internal medicine, and bone marrow transplantation. With over three decades of experience in the medical field, he holds the title of Professor and has made significant contributions to the advancement of hematopoietic stem cell transplantation (HSCT) and hematological research. He earned his MD from the Medical University of Silesia in 1989, followed by a fellowship in 1990. Throughout his career, he has worked in prestigious institutions such as the Medical University of Silesia, Katowice, Poland, and the Albany Medical College in New York. Professor Markiewicz’s research has led to numerous high-impact publications, and he is known for his expertise in myelodysplastic syndrome (MDS), graft-versus-host disease (GVHD), and treatment outcomes in bone marrow transplantation. His commitment to research and clinical excellence has earned him recognition as a leader in his field.

Publication Profile: 

Orcid

Strengths for the Award:

Prof. Mirosław Markiewicz is a leading expert in the field of hematology, particularly in hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and myelodysplastic syndrome (MDS). His vast clinical experience and academic achievements, including over 114 publications with an impressive impact factor (IF 217.467) and a Hirsch Index of 12, demonstrate his dedication to advancing medical science. Prof. Markiewicz’s research contributions have been instrumental in improving patient outcomes in hematology, particularly in understanding conditioning regimens for HSCT, and exploring genetic and environmental factors in diseases like multiple myeloma. His leadership roles in various institutions and collaborative work with other prominent scientists further underscore his position as a top researcher in his field.

Areas for Improvements:

While Prof. Markiewicz has an extensive publication record, further engagement in multi-disciplinary research approaches could strengthen his contributions to immunotherapy and the intersection of hematology and precision medicine. Additionally, more involvement in international collaborative research projects could expand the global impact of his findings.

Education:

Mirosław Markiewicz completed his academic journey at renowned institutions, beginning with his MD degree from the Medical University of Silesia in 1989. He further enhanced his expertise through a fellowship in hematology in 1990. His early career was focused on internal medicine and hematology, which laid the foundation for his future work in hematopoietic stem cell transplantation. In 2008, he achieved habilitation, the Polish equivalent of a postdoctoral qualification, and in 2015, he attained professorship status. Over the years, Professor Markiewicz has continued to enrich his academic portfolio with numerous research accomplishments. He has worked at several leading medical institutions, including the Medical University of Silesia, Katowice, and the Department of Hematology at the University of Masku. His educational journey reflects an unwavering commitment to advancing knowledge in hematology and improving patient care through clinical and laboratory research.

Experience:

Professor Mirosław Markiewicz boasts an extensive career in hematology and bone marrow transplantation. From 1992 to 2001, he served as an Assistant Professor at the Medical University of Silesia, where he began his work in the Department of Hematology and Bone Marrow Transplantation. He subsequently became the Head of the Department of Hematology at the same institution, a role he held from 2001 to 2017. During this period, he contributed to expanding the scope of hematological care and research in Poland. Between 2017 and 2019, Professor Markiewicz held a prominent position as Head of the Department at the Department of Hematology at Rzeszów University. In 2019, he joined the University of Ransomw, continuing his research and clinical leadership in hematology. His vast clinical experience spans diagnosis, treatment, and transplantation, particularly focusing on myelodysplastic syndrome and acute leukemia, among other complex hematological disorders.

Research Focus:

Professor Mirosław Markiewicz’s research primarily revolves around hematopoietic stem cell transplantation (HSCT), bone marrow transplantation (BMT), and the management of hematological malignancies. His work focuses on the clinical outcomes of hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (MDS), acute leukemia, and other hematologic disorders. Additionally, his research explores graft-versus-host disease (GVHD), a common complication following allogeneic stem cell transplantation, and strategies for its prevention and management. One of his primary areas of interest is the use of novel conditioning regimens, such as treosulfan-based conditioning, and their comparison with traditional therapies in improving patient outcomes. Furthermore, Professor Markiewicz has contributed to studies on the genetic predisposition to hematological cancers and the molecular mechanisms of disease progression. His publications, covering clinical trials, transplant outcomes, and immunological factors, have had a significant impact on the field of hematology and transplantation.

Publications Top Notes:

  1. “Alogeneic hematopoietic stem cell transplantation with CD14-selected CITT cells add-back in high-risk patients” 🧬💉
  2. “Hematopoietic stem cell transplantation with minor biocompatibility antigen disparities” ⚖️🧬
  3. “Treating rapid development of unclassified myeloid lineage acute leukaemia with trisomy 6 and U2AF1 mutation” 🔬⚡
  4. “Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS” 📊🔬
  5. “The role of lifestyle and environmental factors in the pathogenesis of multiple myeloma” 🌱🧬
  6. “Fludarabine-treosulfan versus fludarabine-melphalan conditioning in older AML patients” 🧪💉
  7. “Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma” 🧬📚
  8. “Graft-versus-host disease and survival in patients with MDS after treosulfan- versus busulfan-based conditioning” 🔬🧬
  9. “Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation” 🧪🧬
  10. “Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes” 💉⚖️

Conclusion:

Prof. Mirosław Markiewicz’s work represents the cutting edge of hematology research, particularly in stem cell transplantation and the treatment of hematologic malignancies. His academic rigor, innovative research, and clinical expertise make him a deserving candidate for the Research for Best Researcher Award.

 

 

Li Hou | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Li Hou | Cancer Cell Biology | Best Researcher Award

Prof. Li Hou , Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

Li Hou is a distinguished Chief Physician and Director of the Hematology and Oncology Department at Dongzhimen Hospital, affiliated with Beijing University of Chinese Medicine. With a career spanning over 30 years, she has made remarkable contributions in the integration of Traditional Chinese Medicine (TCM) and Western Medicine for treating tumors and blood diseases. A renowned researcher and educator, Hou Li has led over 40 research projects, authored 50+ papers, and published significant work on tumor and blood disease therapies. Her expertise has been recognized with the prestigious “Famous Doctor’s Excellent Demeanor Award” in 2018. Her passion for advancing healthcare through combined approaches has made her a leader in oncology and hematology in China and internationally. 🌟🎓💉

Publication Profile:

Orcid

Strengths for the Award:

Dr. Li Hou is highly deserving of the Best Researcher Award due to her exceptional contributions in integrating Traditional Chinese Medicine (TCM) and Western Medicine for the treatment of hematological diseases and cancers. Her career is distinguished by over 40 research programs and more than 50 published papers, demonstrating her expertise in oncology and hematology. She has authored notable articles in high-impact journals, showcasing her deep understanding of tumor biology and blood disorders. Her leadership in research, coupled with her clinical practice, has led to groundbreaking insights into the treatment of malignancies, including her work on identifying novel drug targets for cancers. Furthermore, her role in academia and professional service, as a key figure in several influential medical associations, highlights her outstanding impact in the medical field. 🌟🧑‍🔬📚

Areas for Improvement:

While Dr. Li Hou research achievements are commendable, expanding her research collaborations internationally could further enhance her impact. Engaging with global research communities may foster new perspectives and facilitate the exchange of ideas, particularly in the context of cutting-edge medical technologies. Additionally, expanding research into the long-term outcomes of integrated therapies in various populations could provide further evidence of the benefits of combining TCM with Western approaches. This would allow her work to gain even more recognition and clinical application worldwide. 🌍🔬

Education:

Li Hou completed her Bachelor’s in Chinese Medicine at Beijing University of Chinese Medicine in 1993. She then pursued her Master’s degree in Integrated Chinese and Western Medicine from the same institution, completing it in 1998. In 2004, she earned her Doctorate in Integrated Chinese and Western Medicine. Her academic journey has been rooted in the application of both traditional and modern methods to treat complex diseases like cancer and blood disorders, providing her with a strong foundation for her career in clinical practice, research, and education. 🎓📚🩺

Experience:

Li Hou clinical career began in 1993 as a resident at Dongzhimen Hospital. By 1999, she advanced to attending physician, and by 2008, she became an associate chief physician. In 2013, she was appointed as Chief Physician at Dongzhimen Hospital, where she has been working ever since. She holds significant leadership roles within the field, including Chairman of several prestigious oncology committees. Additionally, her role as an evaluation expert for the National Natural Science Foundation of China demonstrates her expertise in research. She has been instrumental in combining traditional Chinese medicine with modern treatments in the management of cancer and hematological conditions. 🏥💼👩‍⚕️

Research Focus:

Li Hou research focus revolves around the integration of Traditional Chinese Medicine (TCM) and Western medicine to treat hematological diseases and cancer. She has made significant strides in identifying novel therapeutic approaches, with an emphasis on improving cancer treatment outcomes. Her work includes studying the role of TCM in modulating drug responses and enhancing chemotherapy effectiveness. Through her extensive research, she has contributed to understanding the genetic and molecular mechanisms involved in blood cancer and tumor progression, aiming to optimize patient care and survival rates. Her studies have been published in leading medical journals. 🧬🔬💡

Publications Top Notes:

  • Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome – Journal of Pharmaceutical and Biomedical Analysis (2025)
  • Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia – Computers in Biology and Medicine (2024)
  • Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study – Cancer Medicine (2023)
  • Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis – Clinical Lymphoma Myeloma and Leukemia (2023)
  • Tanshinone IIa Induces Autophagy and Apoptosis via PI3K/Akt/mTOR Axis in Acute Promyelocytic Leukemia NB4 Cells – Evidence-Based Complementary and Alternative Medicine (2021)
  • Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial – Pain Research and Management (2020) 📝📚🎯

Conclusion:

Dr. Li Hou contributions to medicine are profound and multifaceted, blending traditional and modern therapeutic approaches to offer innovative solutions for cancer and blood diseases. Her research has not only advanced scientific knowledge but also improved patient care. As a leader in both clinical practice and research, she exemplifies the qualities of a Best Researcher Award recipient. Through her continued dedication to her work, Dr. Hou Li will undoubtedly remain at the forefront of medical research, driving progress in both China and globally. 🏆💉🩺

 

 

 

 

Iwona Kwiecień | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Iwona Kwiecień | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Iwona Kwiecień , Military Institute of Medicine – National Research Institute , Poland

Iwona Kwiecień, PhD, is an expert in clinical immunology and laboratory medicine. With a strong academic background and extensive experience in medical research, she has dedicated her career to exploring immunological mechanisms in various diseases. She is currently working at the Military Institute of Medicine in Warsaw, where she serves as a lab specialist and lecturer. Dr. Kwiecień holds a PhD in Medical Science with a specialization in immunology from the Medical University of Warsaw. Her research focuses on the immune response in lung cancer, sarcoidosis, and other inflammatory diseases, employing advanced techniques such as multicolor flow cytometry. Her scientific contributions have been recognized globally, and she continues to shape the field of immunology through her research and teaching.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Iwona Kwiecień possesses an impressive academic background and a consistent record of significant contributions to the field of immunology and medical research. With a Ph.D. in Medical Science and immunology, along with expertise in laboratory medicine, hematology, and flow cytometry, Dr. Kwiecień has shown remarkable skill in investigating the immune system’s role in lung cancer and other diseases. Her work on antigenic profiles in the lung cancer microenvironment, macrophage subpopulations in lung cancer, and immune responses in systemic inflammation highlights her strong research abilities. The 2024 habilitation diploma is a testament to her research excellence. Furthermore, Dr. Kwiecień has contributed to the publication of numerous peer-reviewed articles with significant citations and impact, indicating her strong presence in the scientific community.

Areas for Improvement:

While Dr. Kwiecień has demonstrated significant strength in immunological research, expanding her focus to include other cancer types or diseases beyond lung cancer may broaden the scope of her impact. Additionally, fostering greater international collaboration could further enhance the dissemination of her research globally.

Education:

Iwona Kwiecień earned her Master of Science in Laboratory Medicine from the Medical University of Warsaw in 2012. Later, she completed her PhD at the same university’s First Faculty of Medicine, specializing in immunology, with a thesis on regulatory mechanisms of the immune response, which she defended in 2017. She further pursued a specialization in Laboratory Medical Hematology at the Medical University of Silesia in Katowice, Poland, completing it in 2021. Dr. Kwiecień is also set to receive her habilitation diploma from the Military Institute of Medicine-National Research Institute in 2024, based on her scientific achievements in lung cancer immunology. Throughout her academic journey, she has developed expertise in clinical cytology, flow cytometry, and immunological assays, contributing significantly to the scientific community.

Experience:

Dr. Iwona Kwiecień has accumulated substantial experience in the field of laboratory medicine and immunology, working at several prestigious institutions. Since 2017, she has been a laboratory specialist and lecturer at the Military Institute of Medicine-National Research Institute in Warsaw, focusing on flow cytometry and hematology. Her role involves designing, performing, and analyzing complex experiments, as well as providing education and training to students. Prior to her current position, Dr. Kwiecień worked as a research coordinator assistant at BioVirtus Research Site and Clinical Research Group in Warsaw. Her academic career also includes time spent at the University Clinical Center of the Medical University of Warsaw, where she collaborated on various pathology and immunology projects. Dr. Kwiecień’s professional experience extends to overseeing numerous grants and research projects, including her work on macrophage subpopulations and lung cancer.

Awards and Honors:

Dr. Iwona Kwiecień has received several accolades in recognition of her outstanding contributions to science and research. Among her awards is the prestigious “Gold Laurel Graduate” medal for being the best graduate of Laboratory Medicine at the Medical University of Warsaw in 2013. She also received the 2nd award from the Polish Archives of Internal Medicine for her student research on macrophage subpopulations in sarcoidosis in 2014. Additionally, Dr. Kwiecień has been the recipient of numerous research grants, including the 2014-2015 Grant for Young Scientific Researcher from the Medical University of Warsaw. Her work on macrophage subpopulations in lung cancer earned her a statutory grant at the Military Institute of Medicine in 2018-2019. These awards reflect her exceptional research contributions and commitment to advancing the field of clinical immunology and laboratory medicine.

Research Focus:

Dr. Iwona Kwiecień’s research focus lies primarily in the immunology of lung cancer, sarcoidosis, and inflammatory diseases. Her studies have explored immune responses, particularly the role of macrophages, regulatory T cells, and other immune cell populations in disease progression. A key area of her research involves the use of multicolor flow cytometry to assess antigenic profiles of cells in cancer microenvironments. She has contributed to the understanding of how immune cells, such as T cells and macrophages, interact with tumor cells in the context of lung cancer and other inflammatory conditions. Dr. Kwiecień has also researched the impact of systemic inflammation on diseases like obstructive sleep apnea. Her work aims to uncover novel therapeutic targets and provide insights into the immune mechanisms driving various pathologies. Through her research, Dr. Kwiecień continues to contribute valuable knowledge to the fields of clinical immunology and hematology.

Publications Top Notes:

  1. Frequency and spontaneous cytotoxicity of natural killer cells in healthy children: preliminary results 🧬🧒
  2. Association between M1 and M2 macrophages in bronchoalveolar lavage fluid and tobacco smoking in patients with sarcoidosis 💨🫁
  3. Cytometric analysis of perforin expression in NK cells, CD8+, and CD4+ lymphocytes in children with autoimmune Hashimoto’s thyroiditis 👶🦠
  4. T, B, and NKT Cells in Systemic Inflammation in Obstructive Sleep Apnea 😴🩺
  5. Macrophage polarization in interstitial lung diseases 💔🫁
  6. D4+/CD25high/FoxP3+/CD127- regulatory T cells in bronchoalveolar lavage fluid of lung cancer patients 🫀💉
  7. Elevated regulatory T cells, surface and intracellular CTLA‐4 expression and interleukin‐17 in the lung cancer microenvironment in humans 🫀🧪
  8. Elevated Foxp3/CD8 ratio in lung adenocarcinoma metastatic lymph nodes resected by transcervical extended mediastinal lymphadenectomy 🔬💊
  9. Immunophenotype of t cells expressing programmed death-1 and cytotoxic T cell antigen-4 in early lung cancer: local vs. systemic immune response 🎗️🫁
  10. Fas-positive lymphocytes are associated with systemic inflammation in obstructive sleep Apnea syndrome 🛏️🔬

Conclusion:

Dr. Iwona Kwiecień is a highly capable researcher whose work has made substantial contributions to clinical immunology. Her ongoing focus on the immune responses in cancer offers significant potential for advancing cancer diagnostics and therapeutics. With a strong academic and research background, she is undoubtedly a strong candidate for the Best Researcher Award.